Skye Bioscience Inc.(US:SKYE) Prnewswire·2025-12-02 20:40Company Overview - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. The lead product candidate is nimacimab [1]. Class Action Details - A class action was filed on behalf of investors who purchased or acquired Skye securities during the class period from November 4, 2024, to October 3, 2025, due to alleged misleading information regarding the viability of nimacimab [1]. - The allegations include that Skye failed to disclose that nimacimab was less effective than represented and that its clinical, regulatory, and commercial prospects were overstated [2]. Recent Developments - On October 6, 2025, Skye announced topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab, revealing that the monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo. Additionally, preliminary pharmacokinetic analysis indicated lower than expected drug exposure, suggesting a potential need for higher dosing [3]. - Following this announcement, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 per share on the same day [3].